Date: 2017-04-28
Type of information: Granting of a patent
Product name: BI-1206
Compound:
Therapeutic area: Cancer - Oncology
Action mechanism:
- monoclonal antibody. BI-1206 is a fully-human anti-CD32b antagonistic antibody that in addition to directly killing tumour cells is thought to work by maintaining CD20 antibodies on the cell membrane of cancer cells, preventing them from becoming resistant to the current state-of-the-art treatment, rituximab. The antibody has shown promise both in combination with CD20 antibodies and as a single agent in chronic lymphocytic lymphoma (CLL) and other types of NHL, in an extensive package of preclinical studies carried out by Leukaemia & Lymphoma Research-funded scientists at the University of Southampton.
- BI-1206 is currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia.
Company: BioInvent (Sweden)
Disease:
Latest news:
Patents:
- • On April 28, 2017, BioInvent International announced that the European Patent Office, EPO, has communicated its intention to grant the company a patent relating to BI-1206. This patent covers the use of BI-1206, and similarCD32b antibodies, in combination with a CD19, CD20 or CD40 antibody in the treatment of cancer or inflammatory diseases in certain groups of patients. Such a CD20 antibody may, for example, be rituximab The European patent will be granted by the EPO once all remaining administrative actions have been completed by BioInvent. The maximum patent term expires in 2031. The company has earlier been granted a corresponding patent in Australia and has patent applications pending in other countries.
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE:
OTC status:
Other news:
Is general: Yes
